Aduro BioTech, Inc. (NASDAQ:ADRO) reached 73.08% versus a 1-year low price of $2.34. The stock was last seen 10.05% higher, reaching at $4.05 on 02/15/2019. At recent session, the prices were hovering between $3.66 and $4.38. This company shares are 72.84% off its target price of $7 and the current market capitalization stands at $292.21M. The recent change has given its price a 40.64% lead over SMA 50 and -59.19% deficit over its 52-week high. The stock witnessed 44.64% gains, 26.56% gains and -25% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ADRO’s volatility during a week at 8.63% and during a month it has been found around 8.82%.

Aduro BioTech, Inc. (ADRO) Top Holders

Institutional investors currently hold around $153 million or 48.2% in ADRO stock. Look at its top three institutional owners. Wellington Management Group Llp owns $24.18 million in Aduro BioTech, Inc., which represents roughly 8.28% of the company’s market cap and approximately 15.81% of the institutional ownership. Similar statistics are true for the second largest owner, Blackrock Inc., which owns 5,324,644 shares of the stock are valued at $21.57 million. The third largest holder is Baillie Gifford & Co, which currently holds $14.83 million worth of this stock and that ownership represents nearly 5.07% of its market capitalization.

Aduro BioTech, Inc. 13F Filings

At the end of December reporting period, 47 institutional holders increased their position in Aduro BioTech, Inc. (NASDAQ:ADRO) by some 8,091,365 shares, 40 decreased positions by 8,728,215 and 14 held positions by 20,938,779. That puts total institutional holdings at 37,758,359 shares, according to SEC filings. The stock grabbed 15 new institutional investments totaling 4,485,237 shares while 17 institutional investors sold out their entire positions totaling 1,385,677 shares.

Aduro BioTech, Inc. (NASDAQ:ADRO) Insider Trades

Multiple company employees have indulged in significant insider trading. Aduro BioTech, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Chief Scientific Officer Van Elsas Andrea has sold 1,907 shares of Aduro BioTech, Inc. (ADRO) in trading session dated Dec. 28, 2018. These shares are worth $4,901 and were traded at $2.57 each. The SEC filing shows that Van Elsas Andrea performed a sale of 2,171 shares. The Chief Scientific Officer disposed these shares by way of transaction on Dec. 12, 2018. The company’s shares were given away at $2.93 per share worth to an income of some $6,361 on account of Van Elsas Andrea.

President and CEO, Isaacs Stephen T, sold 5,829 common shares of Aduro BioTech, Inc. (ADRO) in the open market. In a transaction dated Dec. 12, 2018, the shares were put up for sale at an average price of $2.93, raking in a sum of $17,079. After this sale, 335,956 common shares of ADRO are directly owned by the insider, with total stake valued at $1,360,622.

In the transaction dated Dec. 12, 2018, the great number of shares disposed came courtesy the Chief Legal Officer; Templeman Blaine disposed a total of 1,241 shares at an average price of $2.93, amounting to approximately $3,636. The insider now directly owns 129,878 shares worth $526,006.

Aduro BioTech, Inc. (ADRO) Analyst Guide

Several analysts have released their opinion on Aduro BioTech, Inc. (NASDAQ:ADRO), with 3 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 2 buy, 1 sell and 0 strong sell ratings, collectively assigning a 1.83 average brokerage recommendation.